Literature DB >> 8851689

Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test.

Z Lević1, D Micić, J Nikolić, N Stojisavljević, D Sokić, S Janković, A Kendereski, M Mavra.   

Abstract

Ten patients in acute exacerbation of multiple sclerosis were treated with 1000 mg of methylprednisolone for 7 days, followed by abrupt cessation of therapy. The function of hypothalamic-pituitary-adrenal (HPA) axis was assessed by the response of ACTH and cortisol to insulin tolerance test (ITT). ITT was performed 1 day before and 1, 3, 8, 13 and 23 days after the termination of the therapy (days 0, 8, 10, 15, 20 and 30 of the study, respectively). The response of these hormones to insulin-induced hypoglycemia prior to therapy was normal. There was no suppression of the ACTH response to hypoglycemia after the methylprednisolone therapy based on the 100% rise of ACTH after ITT. Cortisol response during ITT was suppressed at day 8 (1 day after ending of therapy) but recovered on day 10 (3 days after ending of therapy). In conclusion, 7 day-therapy with 1000 mg methylprednisolone does not result in the permanent suppression of the HPA axis, suggesting that no regular supplemental corticosteroid coverage is required. The observed transitory suppression of the HPA axis recovered spontaneously after the therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8851689     DOI: 10.1007/BF03347855

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

Review 1.  Steroid therapy in multiple sclerosis. Point of view.

Authors:  R Troiano; S D Cook; P C Dowling
Journal:  Arch Neurol       Date:  1987-08

Review 2.  Corticosteroids: clinical pharmacology and therapeutic use.

Authors:  S L Swartz; R G Dluhy
Journal:  Drugs       Date:  1978-09       Impact factor: 9.546

3.  Intravenous methylprednisolone for multiple sclerosis in relapse.

Authors:  M P Barnes; D E Bateman; P G Cleland; D J Dick; T J Walls; P K Newman; M Saunders; P J Tilley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

4.  Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.

Authors:  J L Trotter; W F Garvey
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Assessment of the hypothalamic-pituitary-adrenal axis function after corticosteroid therapy for MS relapses.

Authors:  J Miró; J A Amado; C Pesquera; J J López-Cordovilla; J Berciano
Journal:  Acta Neurol Scand       Date:  1990-06       Impact factor: 3.209

Review 7.  Normal and abnormal function of the hypothalamic-pituitary-adrenocortical system in man.

Authors:  D H Streeten; G H Anderson; T G Dalakos; D Seeley; J S Mallov; R Eusebio; F S Sunderlin; S Z Badawy; R B King
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

8.  High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.

Authors:  L Durelli; D Cocito; A Riccio; C Barile; B Bergamasco; G F Baggio; F Perla; M Delsedime; G Gusmaroli; L Bergamini
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

  9 in total
  3 in total

1.  Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency.

Authors:  Sofie Jespersen; Birte Nygaard; Lars Østergaard Kristensen
Journal:  Eur Thyroid J       Date:  2015-10-27

2.  Hypothalamic-Pituitary-Adrenal Axis Recovery Following the 1-mg Overnight Dexamethasone Suppression Test in Healthy Volunteers.

Authors:  Adlyne Reena Asirvatham; Karthik Balachandran; Shriraam Mahadevan; Satish Kumar Balasubramaniam
Journal:  Int J Endocrinol Metab       Date:  2020-04-21

3.  High Mortality Rate in Oral Glucocorticoid Users: A Population-Based Matched Cohort Study.

Authors:  Margret J Einarsdottir; Per Ekman; Mattias Molin; Penelope Trimpou; Daniel S Olsson; Gudmundur Johannsson; Oskar Ragnarsson
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-08       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.